Earnest Partners LLC Sells 8,196 Shares of Integer Holdings Co. (NYSE:ITGR)

Earnest Partners LLC trimmed its position in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,163,381 shares of the medical equipment provider's stock after selling 8,196 shares during the period. Earnest Partners LLC owned 3.47% of Integer worth $154,171,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of ITGR. Raymond James Financial Inc. bought a new position in Integer during the 4th quarter valued at $38,073,000. Capital Research Global Investors boosted its stake in Integer by 16.0% during the fourth quarter. Capital Research Global Investors now owns 1,410,803 shares of the medical equipment provider's stock valued at $186,960,000 after buying an additional 194,895 shares in the last quarter. Artisan Partners Limited Partnership acquired a new position in Integer during the fourth quarter worth about $22,775,000. Laurus Investment Counsel Inc. bought a new stake in Integer in the fourth quarter worth about $5,422,000. Finally, New York State Common Retirement Fund lifted its holdings in Integer by 20.9% in the 4th quarter. New York State Common Retirement Fund now owns 232,569 shares of the medical equipment provider's stock valued at $30,820,000 after acquiring an additional 40,158 shares during the last quarter. Institutional investors own 99.29% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on ITGR shares. StockNews.com downgraded shares of Integer from a "hold" rating to a "sell" rating in a report on Friday, April 25th. Truist Financial set a $150.00 price objective on Integer and gave the company a "buy" rating in a research report on Friday, April 25th. Oppenheimer cut Integer from an "outperform" rating to a "market perform" rating in a report on Friday, February 21st. Benchmark reduced their target price on Integer from $150.00 to $140.00 and set a "buy" rating for the company in a report on Friday, April 25th. Finally, Raymond James lifted their price target on Integer from $145.00 to $150.00 and gave the stock an "outperform" rating in a research note on Friday, April 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $145.56.

Integer Stock Down 0.6 %

Shares of NYSE:ITGR traded down $0.71 during trading on Thursday, reaching $125.61. 859,917 shares of the company traded hands, compared to its average volume of 350,800. The firm has a fifty day simple moving average of $118.92 and a 200 day simple moving average of $130.18. The company has a quick ratio of 2.09, a current ratio of 2.95 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 1-year low of $104.93 and a 1-year high of $146.36. The firm has a market cap of $4.38 billion, a P/E ratio of 37.38, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The medical equipment provider reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.27 by $0.04. Integer had a return on equity of 11.65% and a net margin of 6.92%. The firm had revenue of $437.39 million during the quarter, compared to analysts' expectations of $428.51 million. During the same quarter last year, the firm earned $1.14 earnings per share. The business's revenue for the quarter was up 7.3% on a year-over-year basis. Analysts anticipate that Integer Holdings Co. will post 6.01 earnings per share for the current fiscal year.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.